**AJP-Cell Physiology** begins a theme series on the control of the proteostasis network in health and diseases

Eric Chevet,1,2 Remy Pedeux,1,2 and Sophie Lotersztajn3

1Inserm ERL440, “Oncogenesis, Stress, Signaling,” Université Rennes 1, Rennes, France; 2Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France; and 3Inserm U1149, Center for Research on Inflammation, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine Xavier Bichat, Paris, France

The maintenance of protein homeostasis (proteostasis) is essential for all functions of cells and the organism and results from a tightly controlled balance between synthesis, folding, and selective degradation of damaged and aggregated proteins. Multiple physiological situations challenge the proteome, including developmental changes or adaptation to environmental stress conditions, as well as the accumulation of misfolded or damaged proteins. In the past few years, characterization of the molecular machinery involved in the maintenance of cellular proteostasis has led to a better understanding of how this process controls physiological and pathological situations, hence allowing the design of novel therapeutic tools.

Protein homeostasis relies on a specific network that integrates numerous molecular partners and that is referred to as the proteostasis network (PN) (1). The PN is a multicompartamental system that coordinates the conserved molecular machines to ensure protein synthesis, folding, quality control, localization, modification, assembly, and turnover (8); Fig. 1.

Although the synthesis and degradation machineries are well characterized individually, the understanding of proteostasis control as a whole still needs to be further documented. Quality control mechanisms ensure the detection and degradation of misfolded proteins to prevent aggregation and deleterious effects of dysfunctional proteins (proteotoxicity). These events are often specific to a particular subcellular compartment (by variation of the composition of PN’s molecular composition) and also depend on a finely tuned coordination of the two major proteolytic pathways, the ubiquitin-proteasome system (UPS) and autophagy (6), and on protein modifications by ubiquitination or sumoylation [Fig. 2 (4, 6)]. The adjustments of the PN in response to variation in protein synthesis/folding demand are ensured by coordination of stress signaling pathways that can also be compartment specific [e.g., endoplasmic reticulum unfolded protein response (UPR)ER (5), mitochondrial unfolded protein response (UPR)mito (7), or heat shock response (3)].

In addition to the common factors required for protein synthesis, maintenance, and turnover, the expression of many PN components is adjusted to the specific protein demands exhibited by different cells and tissues (1). Furthermore, proteostasis control plays instrumental roles throughout development or when organisms/cells are exposed to challenging/disease conditions. As such, the activity of the PN can be altered permanently or transiently by developmental processes (e.g., aging) (8), physiological alterations (e.g., oncogene expression, protein variants), or exposure to environmental stress (e.g., nutrient deprivation, hypoxia, heat) (2). Consequently, protein homeostasis adjustments through PN-mediated control can be viewed as a global adaptive mechanism to cope with the accumulation of misfolded and/or damaged proteins. In addition to this homeostatic function, stress response pathways that are part of the PN can also trigger apoptosis in response to terminal stress. This is well illustrated in the context of the unfolded protein response (5). Thus, temporal and spatial fluctuations in the PN could have profound consequences for disease occurrence and progression.

The proteostasis network is also challenged or rewired in a wide range of diseases, including degenerative, metabolic, inflammatory, and immune diseases, or cancer, and has consequently become an attractive therapeutic target (1). In keeping, pharmacological targeting of the PN has proven successful for the treatment of proteostasis diseases, for instance by the

---

Fig. 1. Schematic representation of the different cellular modules that constitute the proteostasis network.
use of the chemical chaperone phenyl butyrate in patients with cystic fibrosis (10), or proteasome inhibitors in patients with multiple myeloma (9). However, the development of therapeutic strategies targeting the PN has been limited by the size, complexity, dynamics, and partial redundancy of the PN (1). Therefore, the extensive characterization of disease-associated PN(s) may be essential to predict disease outcome as well as drug sensitivity/resistance parameters.

This Review series will cover different aspects of protein homeostasis control. Articles will discuss the involvement of ubiquitin and SUMO proteins in the proteostasis network, as well as their cross talk to yield proper biological outcomes. Protein degradation machineries will also be discussed, including autophagy and coordinated degradation through the proteasome and the lysosome. Finally, deregulation of proteostasis pathways in pathophysiological situations will be illustrated in the context of muscle wasting and cancer. We believe that readers will find the Review articles in this Theme of interest. In addition, we hope that the ideas and results discussed in the articles will stimulate experiments that address unanswered, important questions regarding cellular mechanisms that contribute to the regulation of proteostasis. We look forward to receiving manuscripts that provide such results at AJP-Cell Physiology.

ACKNOWLEDGMENTS

The authors acknowledge networking support by the Proteostasis (BM1307) and Transautophagy (CA 15138) COST actions.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS

E.C. prepared figures; E.C. drafted manuscript; E.C., R.P., and S.L. edited and revised manuscript; E.C., R.P., and S.L. approved final version of manuscript.

REFERENCES